CMMB Insider Trading Activity and SEC Form 4 Filings
CMMB insider trading summary
Over the past 12 months, insiders at Chemomab Therapeutics Ltd. (CMMB) reported 2 open-market purchases worth $20K by 1 insider and 2 sales worth $7K by 1 insider on SEC Form 4. Net insider buying was $14K.
Latest CMMB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 28, 2026 | Neil Harris Cohen | Director | Sell | $3K (1,000 @ $2.80) |
| Aug 27, 2026 | Neil Harris Cohen | Director | Sell | $4K (1,304 @ $2.85) |
| May 29, 2026 | George Adi Mor | Chief Executive Officer | Buy | $10K (4,878 @ $2.05) |
| May 29, 2026 | George Adi Mor | Chief Executive Officer | Buy | $10K (4,926 @ $2.08) |
| Jan 3, 2023 | OrbiMed Israel GP Ltd. | 10% Owner | Sell | $890K (266,376 @ $3.34) |
| Jan 3, 2023 | OrbiMed Israel BioFund GP Limited Partnership | 10% Owner | Sell | $318K (70,524 @ $4.51) |
| Jan 3, 2023 | OrbiMed Israel BioFund GP Limited Partnership | 10% Owner | Sell | $890K (266,376 @ $3.34) |
| Jan 3, 2023 | OrbiMed Israel GP Ltd. | 10% Owner | Sell | $318K (70,524 @ $4.51) |
| Jan 3, 2023 | George Adi Mor | Chief Scientific Officer | Sell | $39K (7,700 @ $5.03) |
| Jan 3, 2023 | George Adi Mor | Chief Scientific Officer | Sell | $31K (6,100 @ $5.03) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.